** Shares of drug developer Ideaya Biosciences IDYA.O fall 4.6% to $20.94
** Co reports Q4 net loss of $130.3 million compared with net loss of $34.0 million a year ago
** Collaboration revenue for the quarter was $7 million compared to $3.9 million a year earlier
** Co received milestone payment from GSK GSK.L
** As of December 31, co had cash, cash equivalents and marketable securities of about $1.1 billion, compared to $632.6 million a year earlier
** Separately, co entered into an additional clinical study collaboration and supply agreement with Gilead Sciences GILD.O to test IDYA's experimental drug, IDE397, in combination with GILD's trodelvy to treat a type of lung cancer
** In the last 12 months, IDYA has fallen ~53%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。